We cumulatively had penetrated into approximately 2,200 hospitals in the PRC, among which over 1,300 hospitals were Class III hospitals.
In September, we passed the milestone of 90,000 neuro-interventional procedures using our products (over 5,000 attributable to Tubridge).
NUMEN and NUMEN FR obtained CE Marking in the European Union in April and FDA registration in the United States and MFDS approval in South Korea in September. The first overseas coil embolization procedure with NUMEN and NUMEN FR was completed in Chile in August, marking NUMEN and NUMEN FR’s entrance to the overseas markets.
We submitted the NMPA registration application of Neurohawk, our self-developed stent retriever system with enhanced full visualization.
We further invested in Rapid Medical and became its largest shareholder.
We completed the 2021 Pre-[REDACTED] Investment with post-money valuation reached US$1.75 billion.